

Riccardo Soffietti

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6800011/riccardo-soffietti-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

209
papers

13,818
citations

58
h-index

116
g-index

235
ext. papers

18,786
ext. citations

5.8
avg. IF

6.35
L-index

#	Paper	IF	Citations
209	Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 134-41	2.2	1369
208	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021 , 23, 1231-1251	1	708
207	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology, The</i> , 2017 , 18, e315-e329	21.7	599
206	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1373-1385	21.7	518
205	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology, The</i> , 2014 , 15, e395-403	21.7	498
204	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009 , 374, 1512-20	40	478
203	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology, The</i> , 2015 , 16, e270-8	21.7	472
202	A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. <i>Journal of Clinical Oncology</i> , 2013 , 31, 65-72	2.2	443
201	EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology, The</i> , 2016 , 17, e383-917	21.7	414
200	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1199-208	1	398
199	Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. <i>European Journal of Neurology</i> , 2010 , 17, 1124-1133	6	374
198	Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. <i>European Journal of Neurology</i> , 2011 , 18, 19-e3	6	332
197	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 5	51.1	283
196	Management of brain metastases. <i>Journal of Neurology</i> , 2002 , 249, 1357-69	5.5	277
195	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology, The</i> , 2015 , 16, e322-32	21.7	247
194	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017 , 19, 162-174	1	244
193	Epidemiology of glial and non-glial brain tumours in Europe. <i>European Journal of Cancer</i> , 2012 , 48, 1532-42	4.5	212

192	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 170-186	19.4	204
191	Prognostic factors in well-differentiated cerebral astrocytomas in the adult. <i>Neurosurgery</i> , 1989 , 24, 686-92	3.2	191
190	Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv55-64	1	162
189	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016 , 18, 1043-65	1	158
188	EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 674-81	6	157
187	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. <i>Nature Medicine</i> , 2018 , 24, 1024-1035	50.5	156
186	PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. <i>Neurosurgery</i> , 1998 , 43, 1066-73	3.2	142
185	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012 , 123, 727-38	14.3	131
184	Histologic prognostic factors in ependymoma. <i>Childs Nervous System</i> , 1991 , 7, 177-82	1.7	122
183	Epilepsy and brain tumors. <i>Current Opinion in Oncology</i> , 2010 , 22, 611-20	4.2	118
182	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , 2014 , 16, 1176-85	7	116
181	Brain metastases: current management and new developments. <i>Current Opinion in Oncology</i> , 2008 , 20, 676-84	4.2	116
180	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 110-119	21.7	116
179	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2468-77	2.2	113
178	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018 , 4, 176-196	12.5	110
177	Ependymomas in adults. <i>Current Neurology and Neuroscience Reports</i> , 2010 , 10, 240-7	6.6	106
176	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , 2017 , 19, 484-492	1	101
175	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , 2018 , 20, 445-456		100

174	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , 14, e407-16	21.7	97
173	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 1994-1999	16.3	93
172	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , 14, e396-406	21.7	92
171	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017 , 19, 625-635	1	87
170	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015 , 17, 440-7	1	83
169	Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 353-66	4.8	82
168	PRE-OPERATIVE CHEMOTHERAPY AS A NEW STRATEGY OF TREATMENT FOR LOW GRADE GLIOMAS IN ELOQUENT AREAS. <i>Neuro-Oncology</i> , 2014 , 16, iii45-iii45	1	78
167	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018 , 8, 161	5.3	72
166	PET imaging in patients with brain metastasis-report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019 , 21, 585-595	1	72
165	The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in Western Patients with intravascular large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008 , 143, 253-7	4.5	70
164	Natural history and management of brainstem gliomas in adults. A retrospective Italian study. <i>Journal of Neurology</i> , 2008 , 255, 171-7	5.5	69
163	Ependymomas of the adult: molecular biology and treatment. <i>Current Opinion in Neurology</i> , 2008 , 21, 754-61	7.1	68
162	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019 , 21, 571-584	1	67
161	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology, The</i> , 2018 , 19, e20-e32	21.7	63
160	Ependymoma: Internal Correlations among Pathological Signs: The Anaplastic Variant. <i>Neurosurgery</i> , 1991 , 29, 206-210	3.2	63
159	Targeted therapy in brain metastasis. <i>Current Opinion in Oncology</i> , 2012 , 24, 679-86	4.2	61
158	Primitive cerebral melanoma: case report and review of the literature. <i>World Neurosurgery</i> , 2001 , 55, 163-8; discussion 168		61
157	Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. <i>Neuro-Oncology</i> , 2013 , 15, 1739-49	1	60

156	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1155-1164	8.8	58
155	Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2014 , 116, 533-41	4.8	58
154	Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 243-247	13.4	56
153	Brain metastases from unknown primary tumour: a prospective study. <i>Journal of Neurology</i> , 2001 , 248, 394-8	5.5	55
152	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019 , 21, 26-36	1	54
151	Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring. <i>BioMed Research International</i> , 2018 , 2018, 3606970	3	47
150	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 744-51	1	46
149	Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. <i>Brain Pathology</i> , 2013 , 23, 584-94	6	45
148	Prognostic value of histologic factors in adult cerebral astrocytoma. <i>Cancer</i> , 1988 , 61, 1386-93	6.4	45
147	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020 , 16, 557-574	15	44
146	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020 , 22, 17-30	1	43
145	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016 , 18, 401-7	1	41
144	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 419-427	4.8	38
143	MGMT promoter methylation in plasma of glioma patients receiving temozolomide. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 347-57	4.8	38
142	Neurologic complications of chemotherapy and other newer and experimental approaches. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014 , 121, 1199-218	3	38
141	Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors. <i>European Journal of Endocrinology</i> , 2006 , 155, 559-66	6.5	37
140	Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. <i>European Journal of Cancer</i> , 2012 , 48, 3439-47	7.5	33
139	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. <i>Cancer</i> , 2004 , 100, 807-13	6.4	33

138	MRI diagnosis of intramedullary metastases from extra-CNS tumors. <i>European Radiology</i> , 1997 , 7, 732-6	8	32
137	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021 , 23, 1821-1834		32
136	Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy. <i>Acta Neuropathologica</i> , 1982 , 58, 291-9	14.3	31
135	Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	28
134	Radiotherapy and chemotherapy of brain metastases. <i>Journal of Neuro-Oncology</i> , 2005 , 75, 31-42	4.8	28
133	What is New in the Management of Epilepsy in Gliomas?. <i>Current Treatment Options in Neurology</i> , 2015 , 17, 351	4.4	27
132	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , 2018 , 19, e33-e42	21.7	27
131	Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. <i>Neuro-Oncology</i> , 2016 , 18, 261-8	1	25
130	Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. <i>Neuro-Oncology</i> , 2021 , 23, 812-826	1	23
129	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021 , 23, 881-893	1	23
128	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. <i>Neuro-Oncology</i> , 2014 , 16, 173-8	1	22
127	Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. <i>Annals of Oncology</i> , 2017 , 28, 2588-2594	10.3	22
126	Prognostic Factors in Adult Medulloblastoma. A Clinico-Pathologic Study. <i>Tumori</i> , 1995 , 81, 338-346	1.7	22
125	Delayed adverse effects after irradiation of gliomas: clinicopathological analysis. <i>Journal of Neuro-Oncology</i> , 1985 , 3, 187-92	4.8	22
124	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. <i>Cancer Letters</i> , 2020 , 480, 24-28	9.9	21
123	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017 , 82, 193-202	7.5	21
122	Breast cancer brain metastasis: molecular mechanisms and directions for treatment. <i>Neuro-Oncology</i> , 2018 , 20, 1439-1449	1	20
121	Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. <i>Journal of Neuro-Oncology</i> , 2018 , 136, 105-114	4.8	20

120	Use of Antidepressants and Risk of Incident Stroke: A Systematic Review and Meta-Analysis. <i>Neuroepidemiology</i> , 2019 , 53, 142-151	5.4	20
119	Radio- and chemotherapy of malignant gliomas. Pathological changes in the normal nervous tissue. <i>Acta Neurochirurgica</i> , 1981 , 58, 37-58	3	20
118	Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. <i>European Radiology</i> , 2016 , 26, 1263-73	8	19
117	Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. <i>BMC Cancer</i> , 2015 , 15, 486	4.8	18
116	A comprehensive characterization of mitochondrial DNA mutations in glioblastoma multiforme. <i>International Journal of Biochemistry and Cell Biology</i> , 2015 , 63, 46-54	5.6	18
115	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019 , 129, 63-71	5.9	18
114	Brain metastases. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 747-553		17
113	New developments in the treatment of malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 1313-26	4.3	17
112	Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009 , 68, 425-31	3.1	16
111	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020 , 22, 1568-1579	1	15
110	New chemotherapy options for the treatment of malignant gliomas. <i>Anti-Cancer Drugs</i> , 2007 , 18, 621-322.4		15
109	Primary Lymphomas of the Brain: A Clinico-Pathologic Review of 37 Cases. <i>Tumori</i> , 1987 , 73, 585-592	1.7	15
108	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. <i>Oncotarget</i> , 2016 , 7, 21190-8	3.3	15
107	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418759618	6.6	13
106	Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 115-123	4.8	12
105	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 45-56	7.1	12
104	Anti-angiogenic approaches to malignant gliomas. <i>Current Cancer Drug Targets</i> , 2012 , 12, 279-88	2.8	12
103	Chemotherapy of anaplastic oligodendroglial tumours. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 295-306		12

102	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2007-2007	2.2	12
101	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 45-56	7.1	12
100	Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. <i>Oncotarget</i> , 2017 , 8, 67696-67708	3.3	12
99	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , 2020 , 64, 313-334	1.3	11
98	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. <i>Neuro-Oncology</i> , 2017 , 19, 451-453	1	10
97	Rare glial tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 399-415	1.5	10
96	Skin metastases of glioblastoma in the absence of intracranial progression are associated with a shift towards a mesenchymal immunophenotype: report of two cases. <i>Acta Neuropathologica</i> , 2009 , 118, 313-6	14.3	10
95	Supratotal Resection of Glioblastoma: Is Less More?. <i>Surgical Technology International</i> , 2019 , 35, 432-440.8	0.8	10
94	Treatment of brain metastasis: current status and future directions. <i>Current Opinion in Oncology</i> , 2016 , 28, 502-510	4.2	9
93	Pharmacologic therapies for malignant glioma: a guide for clinicians. <i>CNS Drugs</i> , 2014 , 28, 1127-37	6.7	9
92	Antiangiogenic therapy of brain tumors: the role of bevacizumab. <i>Neurological Sciences</i> , 2014 , 35, 507-14.5	4.5	9
91	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 225-238	1.4	9
90	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. <i>PLoS ONE</i> , 2018 , 13, e0203570	3.7	9
89	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , 2019 , 126, e270-e280	2.1	8
88	The legend of cytomegalovirus and glioblastoma lives on. <i>Neuro-Oncology</i> , 2014 , 16, 166	1	8
87	Controversies in management of low-grade gliomas in light of new data from clinical trials. <i>Neuro-Oncology</i> , 2017 , 19, 143-144	1	8
86	The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. <i>Seminars in Oncology</i> , 2009 , 36, S55-68	5.5	8
85	Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas. <i>Neuroradiology</i> , 1992 , 34, 73-6	3.2	8

84	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019 , 78, 248-256	3.1	8
83	A call from the European Academy of Neurology on COVID-19. <i>Lancet Neurology</i> , 2020 , 19, 482	24.1	8
82	A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology. <i>European Journal of Neurology</i> , 2021 , 28, 3849-3855	6	8
81	Proliferating Cell Nuclear Antigen (PCNA) in Low-Grade Astrocytomas: Its Prognostic Significance. <i>Tumori</i> , 1994 , 80, 295-300	1.7	7
80	Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. <i>European Journal of Neurology</i> , 2021 , 28, 3226-3229	6	7
79	Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. <i>Neuropathology and Applied Neurobiology</i> , 2019 , 45, 655-670	5.2	6
78	Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?. <i>Neuro-Oncology</i> , 2016 , 18, 12-5	1	6
77	Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. <i>Journal of Neuro-Oncology</i> , 2010 , 97, 439-44	4.8	6
76	Vascular response to irradiation in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 1990 , 8, 73-84	4.8	6
75	Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study. <i>Oncotarget</i> , 2020 , 11, 4648-4654	3.3	6
74	Management of Brain and Leptomeningeal Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
73	Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. <i>Cancers</i> , 2021 , 13,	6.6	6
72	Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Delayed Administration. <i>Anticancer Research</i> , 2018 , 38, 5877-5881	2.3	6
71	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , 2019 , 21, 1610-1611	1	5
70	Extent of surgery in low-grade gliomas: an old question in a new context. <i>Neuro-Oncology</i> , 2018 , 20, 6-7	1	5
69	Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage. <i>Tumori</i> , 2015 , 101, e167-70	1.7	5
68	Still a long way to go to achieve multidisciplinary for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9-15, 2014). <i>Annals of Oncology</i> , 2014 , 25, 1863-1865	10.3	5
67	Effects of radiotherapy on the astrocytomatous areas of malignant gliomas. <i>Journal of Neuro-Oncology</i> , 1984 , 2, 167-75	4.8	5

66	Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor. <i>Journal of Neurosurgical Sciences</i> , 2018 , 62, 229-232	1.3	5
65	Evaluation of the 2020 European Academy of Neurology virtual congress: transition from a face-to-face to a virtual meeting. <i>European Journal of Neurology</i> , 2021 , 28, 2523-2532	6	5
64	Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series. <i>World Neurosurgery</i> , 2019 , 123, e273-e279	2.1	5
63	What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?. <i>Current Treatment Options in Neurology</i> , 2018 , 20, 33	4.4	5
62	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021 , 156, 93-108	7.5	5
61	Molecularly based management of gliomas in clinical practice. <i>Neurological Sciences</i> , 2015 , 36, 1551-7	3.5	4
60	Evidence-based management of adult patients with diffuse glioma - AuthorsReply. <i>Lancet Oncology, The</i> , 2017 , 18, e430-e431	21.7	4
59	Imaging and clinical end points in brain metastases trials. <i>CNS Oncology</i> , 2017 , 6, 243-246	4	4
58	Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response. <i>Journal of Neuro-Oncology</i> , 2016 , 127, 201-3	4.8	3
57	Neuro-oncology perspective of treatment options in metastatic breast cancer. <i>Future Oncology</i> , 2018 , 14, 1765-1774	3.6	3
56	Neuro-oncology: new insights and advances in treatment. <i>Lancet Neurology, The</i> , 2008 , 7, 14-6	24.1	3
55	The position of the neurologist in neuro-oncology. <i>European Journal of Neurology</i> , 2002 , 9, 201-5	6	3
54	On the Nature of the So-Called Monstrocellular Sarcoma of the Brain. <i>Neurosurgery</i> , 1980 , 6, 391-397	3.2	3
53	Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2037-2037	2.2	3
52	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2047-2047	2.2	3
51	Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
50	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. <i>Cancers</i> , 2021 , 13,	6.6	3
49	Strategies to prevent brain metastasis. <i>Current Opinion in Oncology</i> , 2019 , 31, 493-500	4.2	3

48	Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. <i>Neurology</i> , 2019 , 93, 217-219	6.5	2
47	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. <i>Current Opinion in Neurology</i> , 2020 , 33, 707-715	7.1	2
46	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2045-2045	2.2	2
45	Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents. <i>Cancers</i> , 2020 , 12,	6.6	2
44	Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature. <i>Frontiers in Neurology</i> , 2021 , 12, 669493	4.1	2
43	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1272-1275	2.7	2
42	Natural History and Spontaneous Prognostic Factors 2013 , 265-275		2
41	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.. <i>EMBO Molecular Medicine</i> , 2022 , e14552	12	2
40	Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program.. <i>Cancers</i> , 2022 , 14,	6.6	2
39	Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery. <i>Clinical and Experimental Metastasis</i> , 2020 , 37, 499-508	4.7	1
38	Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. <i>Neurological Sciences</i> , 2016 , 37, 2019-2023	3.5	1
37	Ependymoma: current treatment options and a look to the future. <i>CNS Oncology</i> , 2013 , 2, 223-5	4	1
36	Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression. <i>Journal of Clinical Oncology</i> , 2013 , 31, e394-7	2.2	1
35	Reply to M.C. Chamberlain and C. Gemici. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2636-7	2.2	1
34	Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 551-67	3	1
33	Cranial and Spinal Meningeal Carcinomatosis MR Findings. <i>The Neuroradiology Journal</i> , 1997 , 10, 585-595		1
32	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2056-2056	2.2	1
31	Systemic Therapy for Lung Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 110	5.4	1

30	IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. <i>Neuro-Oncology</i> , 2021 ,	1	1
29	Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2021 ,	1	1
28	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 1037-1048	3.5	1
27	Richter's Syndrome of the Central Nervous System. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-4	1	1
26	Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
25	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , 2018 , 31, 168-179	1.4	0
24	Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy. <i>Journal of Neurosurgical Sciences</i> , 2018 , 62, 375-378	1.3	0
23	Ependymoma: Evaluation and Management Updates.. <i>Current Oncology Reports</i> , 2022 , 1	6.3	0
22	Ependymomas 2017 , 907-916		
21	Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?. <i>Neuro-Oncology</i> , 2017 , 19, 1292-1293	1	
20	Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. <i>Neurological Sciences</i> , 2020 , 41, 1955-1957	3.5	
19	Brain Metastasis as Complication of Systemic Cancers 2018 , 57-79		
18	Spinal epidural metastases 2016 , 596-598		
17	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 20-26	1.6	
16	A Pathologic Study of Malignant Gliomas Operated after Radio- and Chemotherapy. <i>Tumori</i> , 1981 , 67, 13-17	1.7	
15	IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2050-2050	2.2	
14	Brain Metastases [Clinical Challenges and Recent Advances. <i>European Neurological Review</i> , 2019 , 14, 20	0.5	
13	Epilepsy in CNS Metastases 2020 , 117-125		

- 12 Prevention Strategies for Brain Metastasis **2020**, 397-406
- 11 Leptomeningeal metastases: A rano proposal for response criteria.. *Journal of Clinical Oncology*, **2014**, 32, e13019-e13019 2.2
- 10 MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide.. *Journal of Clinical Oncology*, **2014**, 32, 2016-2016 2.2
- 9 GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. *Journal of Clinical Oncology*, **2015**, 33, 2054-2054 2.2
- 8 Is there a Role for Bevacizumab in Non-Glial Tumors?. *Current Drug Targets*, **2015**, 16, 684-8 3
- 7 Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).. *Journal of Clinical Oncology*, **2016**, 34, 2047-2047 2.2
- 6 Natural History and Spontaneous Prognostic Factors **2017**, 307-322
- 5 A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study.. *Journal of Clinical Oncology*, **2017**, 35, 2026-2026 2.2
- 4 Ependymomas **2011**, 249-262
- 3 Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?. *Neuro-Oncology*, **2020**, 22, 171-172 1
- 2 Tumors of the Central Nervous System: Therapeutic Approaches **2019**, 69-83
- 1 Evidence-based approaches to chemotherapy for gliomas **2021**, 38-52